Hydrophobic benzoic acids as inhibitors of influenza neuraminidase

被引:38
|
作者
Atigadda, VR
Brouillette, WJ [1 ]
Duarte, F
Babu, YS
Bantia, S
Chand, P
Chu, NM
Montgomery, JA
Walsh, DA
Sudbeck, E
Finley, J
Air, GM
Luo, M
Laver, GW
机构
[1] Univ Alabama, Dept Chem, Birmingham, AL 35294 USA
[2] Univ Alabama, Ctr Macromol Crystallog, Birmingham, AL 35294 USA
[3] BioCryst Pharmaceut Inc, Birmingham, AL 35244 USA
[4] Univ Oklahoma, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA
[5] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia
关键词
neuraminidase; influenza virus; sialidase; structure-based drug design;
D O I
10.1016/S0968-0896(99)00197-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neuraminidase (NA) plays a critical role in the life cycle of influenza virus and is a target for new therapeutic agents. A new benzoic acid inhibitor (11) containing a lipophilic side chain at C-3 and a guanidine at C-5 was synthesized. The X-ray structure of 4-(N-acetylamino)-5-guanidino-3-(3-pentyloxy)benzoic acid in complex with NA revealed that the lipophilic side chain binds in a newly created hydrophobic pocket formed by the movement of Glu 278 to interact with Arg 226, whereas the guanidine of 11 interacts In a negatively charged pocket created by Asp 152, Glu 120 and Glu 229. Compound 11 was highly selective for type A (H2N2) influenza NA (IC50 1 mu M) over type B (B/Lee/40) influenza NA (IC50 500 mu M). (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2487 / 2497
页数:11
相关论文
共 50 条
  • [11] Prescription of neuraminidase inhibitors for influenza
    Madeley, D
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2003, 96 (04) : 207 - 208
  • [12] Treatment of influenza with neuraminidase inhibitors
    Beard, Kate R.
    Brendish, Nathan J.
    Clark, Tristan W.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2018, 31 (06) : 514 - 519
  • [13] Influenza virus neuraminidase inhibitors
    Gubareva, LV
    Kaiser, L
    Hayden, FG
    LANCET, 2000, 355 (9206): : 827 - 835
  • [14] Neuraminidase inhibitors for influenza complications
    Del Mar, Chris
    Doshi, Peter
    Hama, Rokuro
    Jones, Mark
    Jefferson, Tom
    Heneghan, Carl
    Onakpoya, Igho
    Howick, Jeremy
    LANCET, 2014, 384 (9950): : 1260 - 1261
  • [15] Safety of neuraminidase inhibitors for influenza
    Jones, Mark
    Del Mar, Chis
    EXPERT OPINION ON DRUG SAFETY, 2006, 5 (05) : 603 - 608
  • [16] Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping
    Brouillette, WJ
    Atigadda, VR
    Luo, M
    Air, GM
    Babu, YS
    Bantia, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (14) : 1901 - 1906
  • [17] Influenza virus resistance to neuraminidase inhibitors
    Samson, Melanie
    Pizzorno, Andres
    Abed, Yacine
    Boivin, Guy
    ANTIVIRAL RESEARCH, 2013, 98 (02) : 174 - 185
  • [18] A QSAR study on influenza neuraminidase inhibitors
    Verma, RP
    Hansch, C
    BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (04) : 982 - 996
  • [19] Neuraminidase Inhibitors and Influenza Infection Reply
    Louie, Janice K.
    Lampiris, Harry
    JAMA INTERNAL MEDICINE, 2016, 176 (03) : 416 - 417
  • [20] Neuraminidase inhibitors for influenza complications Reply
    Nguyen-Van-Tam, Jonathan S.
    Openshaw, Peter J. M.
    Nicholson, Karl G.
    LANCET, 2014, 384 (9950): : 1261 - 1262